查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423610

2030 年祛痰药市场预测：按产品、剂型、药物类型、通路、最终用户和地区进行的全球分析

Expectorant Drugs Market Forecasts to 2030 - Global Analysis By Product (Prescription Drug and Over the Counter (Otc)), Dosage Form (Oral Solid, Oral Liquid and Inhalant), Drug Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球祛痰药市场规模为 171.6 亿美元，预计到 2030 年将达到 453.8 亿美元，预测期内复合年增长率为 14.9%。

祛痰药是主要用于促进清除呼吸道（尤其是呼吸系统）中的黏液和分泌物的药物。这些药物的作用是稀释或鬆弛肺部黏液，使其更容易排放。它通常用于缓解与呼吸道疾病相关的症状，例如咳嗽、鼻塞和呼吸道感染疾病。

根据美国国家生物技术资讯中心发布的资料，全球基层医疗医生就诊中约有 8% 是因咳嗽引起的。

呼吸道疾病盛行率上升

随着患有支气管炎、慢性阻塞性肺病、气喘、呼吸道感染疾病等呼吸系统疾病的人数增加，对药品特别是祛痰药的需求也不断增加。这些药物在控制这些疾病的特征症状（如黏液分泌过多、咳嗽和胸闷）方面发挥着至关重要的作用。由于空气污染、生活方式改变和感染疾病因素，呼吸道疾病变得更加常见，对祛痰药缓解症状和改善呼吸道健康的持续需求正在推动市场成长。

副作用增加

祛痰药市场受到日益增加的副作用的严重限制。由于这些药物旨在透过稀释黏液来缓解呼吸道症状，因此越来越多的副作用（例如噁心、头晕和过敏反应）报告影响了患者的耐受性和依从性。副作用发生率的增加可能会抑制患者的医嘱遵从性，降低对这些药物的信心，并影响市场需求。

技术进步

持续的技术创新是开发先进药物配方、改进给药系统和增强祛痰药功效的驱动力。新技术正在创造创新的配方，促进有针对性的药物输送到受影响的呼吸道区域，并优化治疗结果和患者的依从性。此外，个人化医学和药物基因组学的进步可能会带来量身定制的祛痰治疗，确保更有效和个人化的治疗方法。这些进步的结合将解决未满足的医疗需求，并推动祛痰药市场的成长和创新。

监管障碍

复杂的法律规范、不同的地区要求和延长的核准时间是引入新祛痰药的障碍。克服这些障碍需要在研发方面进行大量投资、严格遵守严格的监管准则以及与监管机构的有效合作。如果无法克服这些挑战，可能会阻碍创新祛痰药的及时推出并限制市场成长。

COVID-19 的影响

随着人们开始关注与 COVID-19 相关的咳嗽和胸闷等呼吸道症状，对祛痰药的需求激增。这场大流行促使对呼吸系统健康的研究增加，这可能会导致新开发。此外，即使在大流行的早期阶段，对祛痰药的需求也可能会持续存在，因为 COVID-19 对呼吸道健康有长期影响，且呼吸道问题可能持续存在。

黏液溶解剂领域预计将在预测期内成为最大的领域

据估计，粘液溶解剂领域占最大份额。黏液溶解药物包括溴己新、乙酰半胱胺酸和氨溴索等药物，它们透过破坏黏液中的化学键来降低黏液的黏度，使其更容易排放。黏液溶解剂用于治疗多种呼吸系统疾病，如慢性支气管炎、COPD（慢性阻塞性肺病）和囊肿纤维化，以帮助排放多余的黏液并缓解充血症状。此外，标靶和改变黏液特性的能力使其成为治疗呼吸道疾病的重要因素。

预计医院部门在预测期内将呈现最高的复合年增长率

预计医院产业在预测期内将出现良好的成长。医院是祛痰药的主要买家和卖家，因为它们是呼吸系统疾病诊断和治疗的主要中心。医院采购各种祛痰药来治疗急性和慢性呼吸道疾病的患者，包括肺炎、支气管炎和慢性阻塞性肺病恶化。此外，医院保持充足的这些药物库存，以满足住院患者呼吸护理、急诊治疗和慢性病管理的多样化呼吸健康需求，从而扩大了祛痰药市场。

比最大的地区

由于呼吸道疾病的增加、污染水平的上升以及遭受季节性性行为感染的人口的增加，亚太地区在预测期内占据了最大的市场占有率。此外，都市化、生活方式的改变和环境污染物等因素会导致呼吸道疾病，进而推动对祛痰药的需求。主要市场参与者投资研发以探索和获得负担得起的医疗保健，促进了亚太地区祛痰药市场的快速成长。我们满足您的健康需求。

复合年增长率最高的地区：

由于支气管炎、流感和过敏等疾病的流行，预计北美在预测期内将出现盈利成长。该地区强大的医疗基础设施、先进的药物研究以及意识层级正在推动市场成长。此外，药物开发的策略性倡议、强有力的法规结构、专注于技术创新和产品多元化的主要市场参与者的存在进一步推动了北美祛痰药市场的发展。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球祛痰药市场：按产品

  • 处方药
  • 店面销售(OTC)

第六章全球祛痰药市场：按剂型

  • 口服固态
  • 口服液
  • 吸入剂

第七章全球祛痰药市场：依药物类型

  • 分泌刺激剂
    • 柠檬酸钾
    • 柠檬酸钠
    • 氯化铵
  • 黏液溶解剂
    • 溴己新
    • 氨溴索
    • 碳半胱氨酸尿素
    • 乙酰半胱胺酸
  • 其他类型的药物

第八章全球祛痰药市场：依通路划分

  • 药局
  • 零售店
  • 网路药房
  • 其他分销管道

第九章全球祛痰药市场：依最终用户分类

  • 医院
  • 专业中心
  • 居家护理
  • 其他最终用户

第十章全球祛痰药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Abbott Laboratories
  • Astrazeneca Plc.
  • Acella Pharmaceuticals LLC
  • Cipla Limited
  • Beckman Coulter Inc.
  • Mylan NV
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Johnson and Johnson
  • Novartis International AG
  • Merck KGaA
  • Pfizer inc
  • Sanofi SA
  • Vernalis plc
  • Proctor and Gamble Co
  • Dahur india Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Tris Pharma Inc.
  • Aurobindo Pharma Ltd
  • Biocon
Product Code: SMRC24844

According to Stratistics MRC, the Global Expectorant Drugs Market is accounted for $17.16 billion in 2023 and is expected to reach $45.38 billion by 2030 growing at a CAGR of 14.9% during the forecast period. Expectorant drugs are medications primarily used to facilitate the removal of mucus and secretions from the airways, particularly in the respiratory tract. These drugs work by thinning and loosening mucus in the lungs, making it easier to cough up and expel. They are commonly used to alleviate symptoms associated with respiratory conditions such as cough, congestion, and respiratory infections.

According to data released by the National Center for Biotechnology Information, cough accounted for about 8% of all consultations with primary care physicians worldwide.

Market Dynamics:

Driver:

Rising prevalence of respiratory conditions

With an increasing number of individuals affected by respiratory ailments like bronchitis, COPD, asthma, and respiratory infections, the demand for medications, particularly expectorant drugs, rises correspondingly. These medications play a pivotal role in managing the hallmark symptoms of these conditions, such as excessive mucus production, coughing, and chest congestion. As respiratory illnesses become more commonplace due to factors like air pollution, changing lifestyles, and infectious agents, the consistent need for expectorant drugs to alleviate symptoms and improve respiratory health drives market growth.

Restraint:

Increased side effects

The market for expectorant drugs is severely constrained by the growing number of adverse effects. As these medications aim to alleviate respiratory symptoms by thinning mucus, the rise in reported adverse effects like nausea, dizziness, or allergic reactions impacts patient tolerance and compliance. Heightened occurrences of side effects can deter patient adherence, leading to reduced confidence in these medications and potentially affecting market demand.

Opportunity:

Advancements in technology

Ongoing innovations drive the development of advanced drug formulations, improved delivery systems, and enhanced efficacy of expectorant medications. Novel technologies facilitate targeted drug delivery to affected respiratory areas, creating innovative formulations that optimise treatment outcomes and patient compliance. Additionally, advancements in personalised medicine and pharmacogenomics may lead to tailored expectorant therapies, ensuring more effective and personalised treatment approaches. Embracing these advancements addresses unmet medical needs, fostering growth and innovation in the expectorant drugs market.

Threat:

Regulatory hurdles

Complex regulatory frameworks, diverse regional requirements, and extended approval timelines create obstacles for introducing new expectorant medications. Overcoming these hurdles demands substantial investments in research and development, meticulous adherence to stringent regulatory guidelines, and effective collaboration with regulatory bodies. Failure to navigate these challenges can impede the timely introduction of innovative expectorant drugs, limiting market growth.

Covid-19 Impact

There was a surge in demand for expectorant drugs due to the emphasis on managing respiratory symptoms associated with COVID-19, such as cough and chest congestion. The pandemic prompted increased research into respiratory health, potentially leading to the development of new and improved expectorant drugs or formulations. Furthermore, during the initial pandemic phase, there may be a continuing need for expectorant medications due to the COVID-19's long-lasting effects on respiratory health and possible long-term respiratory problems.

The mucolytics segment is expected to be the largest during the forecast period

The mucolytics segment is estimated to hold the largest share. Mucolytics contain agents such as bromhexine, acetylcysteine, or ambroxol that work by disrupting the chemical bonds within mucus, making it less viscous and easier to expel through coughing. Mucolytics find application in various respiratory conditions like chronic bronchitis, COPD (chronic obstructive pulmonary disease), and cystic fibrosis, aiding in the clearance of excessive mucus and alleviating symptoms of congestion. Furthermore, their ability to target and modify the properties of mucus makes them a crucial component in managing respiratory disorders.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. Hospitals serve as major purchasers and distributors of expectorant drugs due to their role as primary centres for diagnosing and treating respiratory conditions. They procure a wide range of expectorant medications to manage patients with acute and chronic respiratory ailments, including pneumonia, bronchitis, and COPD exacerbations. In addition, hospitals maintain adequate stocks of these drugs to address the diverse respiratory health needs of patients admitted for respiratory care, emergency treatments, or chronic disease management, thereby significantly contributing to the demand within the expectorant drug market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising respiratory ailments, increasing pollution levels, and a larger population affected by seasonal infections. Furthermore, factors like urbanisation, changing lifestyles, and environmental pollutants contribute to respiratory issues, driving the demand for expectorant medications. Initiatives for affordable healthcare access and the presence of key market players investing in research and development contribute to the region's burgeoning expectorant drug market, catering to the diverse respiratory health needs of the Asia Pacific population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to prevalent conditions like bronchitis, flu, and allergies. The region's robust healthcare infrastructure, advanced pharmaceutical research, and high awareness levels among the population about managing respiratory health issues foster market growth. Moreover, strategic initiatives for drug development, strong regulatory frameworks, and the presence of key market players focusing on innovation and product diversification further propel the North American expectorant drug market.

Key players in the market

Some of the key players in the Expectorant Drugs Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Beckman Coulter Inc., Mylan N.V., GSK plc, Glenmark Pharmaceuticals Limited, Johnson and Johnson, Novartis International AG, Merck KGaA, Pfizer inc, Sanofi SA, Vernalis plc, Proctor and Gamble Co, Dahur india Ltd, Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Aurobindo Pharma Ltd and Biocon.

Key Developments:

In October 2023, Efficient Laboratories, a Puerto Rican firm that distributes its brands of healthcare products, launched a new product, ROMPR PECHITO, an OTC medicine for children to relieve cold symptoms.

In September 2023, Genexa announced new clean over-the-counter (OTC) kids' medicines, further strengthening its leading role in bringing consumers clean, safe, and effective medications.

Products Covered:

  • Prescription Drug
  • Over the Counter (Otc)

Dosage Forms Covered:

  • Oral Solid
  • Oral Liquid
  • Inhalant

Drug Types Covered:

  • Secretion Enhancer
  • Mucolytics
  • Other Drug Types

Distribution Channels Covered:

  • Drug Store
  • Retail Store
  • Online Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Expectorant Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Prescription Drug
  • 5.3 Over The Counter (Otc)

6 Global Expectorant Drugs Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Oral Solid
  • 6.7 Oral Liquid
  • 6.8 Inhalant

7 Global Expectorant Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Secretion Enhancer
    • 7.2.1 Potassium Citrate
    • 7.2.2 Sodium Citrate
    • 7.2.3 Ammonium Chloride
  • 7.3 Mucolytics
    • 7.3.1 Bromhexine
    • 7.3.2 Ambroxol
    • 7.3.3 Carbocisteineurine
    • 7.3.4 Acetyl Cysteine
  • 7.4 Other Drug Types

8 Global Expectorant Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Drug Store
  • 8.3 Retail Store
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Expectorant Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Expectorant Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Astrazeneca Plc.
  • 12.3 Acella Pharmaceuticals LLC
  • 12.4 Cipla Limited
  • 12.5 Beckman Coulter Inc.
  • 12.6 Mylan N.V.
  • 12.7 GSK plc
  • 12.8 Glenmark Pharmaceuticals Limited
  • 12.9 Johnson and Johnson
  • 12.10 Novartis International AG
  • 12.11 Merck KGaA
  • 12.12 Pfizer inc
  • 12.13 Sanofi SA
  • 12.14 Vernalis plc
  • 12.15 Proctor and Gamble Co
  • 12.16 Dahur india Ltd
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • 12.18 Tris Pharma Inc.
  • 12.19 Aurobindo Pharma Ltd
  • 12.20 Biocon

List of Tables

  • Table 1 Global Expectorant Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Expectorant Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Expectorant Drugs Market Outlook, By Prescription Drug (2021-2030) ($MN)
  • Table 4 Global Expectorant Drugs Market Outlook, By Over The Counter (Otc) (2021-2030) ($MN)
  • Table 5 Global Expectorant Drugs Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 6 Global Expectorant Drugs Market Outlook, By Oral Solid (2021-2030) ($MN)
  • Table 7 Global Expectorant Drugs Market Outlook, By Oral Liquid (2021-2030) ($MN)
  • Table 8 Global Expectorant Drugs Market Outlook, By Inhalant (2021-2030) ($MN)
  • Table 9 Global Expectorant Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 10 Global Expectorant Drugs Market Outlook, By Secretion Enhancer (2021-2030) ($MN)
  • Table 11 Global Expectorant Drugs Market Outlook, By Potassium Citrate (2021-2030) ($MN)
  • Table 12 Global Expectorant Drugs Market Outlook, By Sodium Citrate (2021-2030) ($MN)
  • Table 13 Global Expectorant Drugs Market Outlook, By Ammonium Chloride (2021-2030) ($MN)
  • Table 14 Global Expectorant Drugs Market Outlook, By Mucolytics (2021-2030) ($MN)
  • Table 15 Global Expectorant Drugs Market Outlook, By Bromhexine (2021-2030) ($MN)
  • Table 16 Global Expectorant Drugs Market Outlook, By Ambroxol (2021-2030) ($MN)
  • Table 17 Global Expectorant Drugs Market Outlook, By Carbocisteineurine (2021-2030) ($MN)
  • Table 18 Global Expectorant Drugs Market Outlook, By Acetyl Cysteine (2021-2030) ($MN)
  • Table 19 Global Expectorant Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 20 Global Expectorant Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 21 Global Expectorant Drugs Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 22 Global Expectorant Drugs Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 23 Global Expectorant Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 24 Global Expectorant Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 25 Global Expectorant Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Expectorant Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Expectorant Drugs Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 28 Global Expectorant Drugs Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 29 Global Expectorant Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.